长效肽设计 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-21 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
== Early life and education == Klaus Mosbach was born in Leipzig, Germany. Family status: Married to May E., three daughters (Petra, Katja, Vanja). Klaus Mosbach went to school in Leipzig Germany and Lund, Sweden, In 1952 he moved to London, where he took Cambridge and interpreter exams. After working in a pharmaceutical company, Ferrosan in Malmö, Sweden, he began his university studies at Lund University 1953. In 1956 he took his master's degree in chemistry and biology and subsequently in 1960 his Ph.D. in biochemistry with a thesis on "the biosynthesis of aromatic compounds in fungi and lichens". He was then awarded the Waksman-Merck post-doctoral fellowship and stayed for 1.5 years at the Institute of Microbiology, Rutgers University, N.J., USA... In 1962 he developed, jointly with Dr. Schaffner in the Philippines, a pasteurization process against Salmonella infections in coconuts, which subsequently was approved by the Food and Drug Administration and is presently used. After returning to Sweden, he continued his studies on secondary metabolism. He received his second Ph.D. (corresponding to associate professorship or "Habilitation") from the University of Lund in 1964. Until 1970 he was associate professor there, and from 1970 onwards he has been full professor and head of the Department of Pure and Applied Biochemistry, which he founded, at Lund Institute of Technology. He also co-founded the Department of biotechnology at the Swiss Federal Institute of Technology ETH Zurich, Switzerland, in 1982.
Notch family members play a role in a variety of developmental processes by controlling cell fate decisions. The Notch signaling network is an evolutionarily conserved intercellular signaling pathway that regulates interactions between physically adjacent cells. In Drosophila, notch interaction with its cell-bound ligands (delta, serrate) establishes an intercellular signaling pathway that plays a key role in development. This protein functions as a receptor for membrane bound ligands, and may play multiple roles during development. A deficiency can be associated with bicuspid aortic valve. There is evidence that activated Notch 1 and Notch 3 promote differentiation of progenitor cells into astroglia. Notch 1, then activated before birth, induces radial glia differentiation, but postnatally induces the differentiation into astrocytes. One study shows that Notch-1 cascade is activated by Reelin in an unidentified way. Reelin and Notch1 cooperate in the development of the dentate gyrus, according to another.
freezing point Also crystallization point. The temperature at which a substance changes state from a liquid to a solid. Because freezing is the reverse of melting, the freezing point of a substance is identical to its melting point, but by convention only the melting point is referred to as a characteristic property of a substance.
Sources: en.wikipedia.org
== Protection & Formation == Fmoc-carbamate is frequently used as a protecting group for primary and secondary amines, where the Fmoc group can be introduced by reacting the amine with fluorenylmethyloxycarbonyl chloride (Fmoc-Cl), e.g.:
Barnum Brown, assistant curator of the American Museum of Natural History, found the first partial skeleton of T. rex in eastern Wyoming in 1900. Brown found another partial skeleton in the Hell Creek Formation in Montana in 1902, comprising approximately 34 fossilized bones. Writing at the time Brown said "Quarry No. 1 contains the femur, pubes, humerus, three vertebrae and two undetermined bones of a large Carnivorous Dinosaur not described by Marsh. ... I have never seen anything like it from the Cretaceous." Henry Fairfield Osborn, president of the American Museum of Natural History, named the second skeleton T. rex in 1905. The generic name is derived from the Greek words τύραννος (tyrannos, meaning "tyrant") and σαῦρος (sauros, meaning "lizard"). Osborn used the Latin word rex, meaning "king", for the specific name. The full binomial therefore translates to "tyrant lizard the king" or "King Tyrant Lizard", emphasizing the animal's size and presumed dominance over other species of the time.
Cone snails, or cones, are highly venomous sea snails that constitute the family Conidae. Conidae is a taxonomic family (previously subfamily) of predatory marine gastropod molluscs in the superfamily Conoidea. As of 2014, cone snails are the only member of the superfamily Conoidea. Some previous classifications grouped the cone snails in a subfamily, Coninae. As of March 2015 Conidae contained over 800 recognized species, varying widely in size from lengths of 1.3 cm to 21.6 cm. Working in 18th-century Europe, Carl Linnaeus knew of only 30 species that are still considered valid. Fossils of cone snails have been found from the Eocene to the Holocene epochs. Cone snail species have shells that are roughly conical in shape. Many species have colorful patterning on the shell surface. Cone snails are almost exclusively tropical in distribution. All cone snails are venomous and capable of stinging. Cone snails use a modified radula tooth and a venom gland to attack and paralyze their prey before engulfing it. The tooth, which is likened to a dart or a harpoon, is barbed and can be extended some distance out from the head of the snail at the end of the proboscis. Cone snail venoms are mainly peptide-based, and contain many different toxins that vary in their effects. The sting of several larger species of cone snails can be serious, and even fatal to humans. Cone snail venom also shows promise for medical use.
This so-called reconciliation bill is in fact a big retaliation bill—retaliation against AFGE and other unions for successfully standing up for our members and fighting this administration's illegal attempts to obliterate our federal agencies and the patriotic civil servants who run our federal programs. These provisions represent a direct assault on federal employees and their labor unions and will make it that much harder for federal agencies to recruit and retain the qualified employees they desperately need to serve the American public. The 2001 recipient of the Nobel Memorial Prize in Economic Sciences, Joseph Stiglitz, was asked about the OBBBA in an interview with Swiss Radio and Television (SRF) as to how he would describe the legislation, to which he had replied:
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。